FDA label E415C4C8-3144-4172-94A0-F4F3243130AE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
E415C4C8-3144-4172-94A0-F4F3243130AE
SPL ID
E415C4C8-3144-4172-94A0-F4F3243130AE
Version
1
Effective date
2006-03-28
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:25:06

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS The safety of Targretin ® gel has been assessed in clinical studies of 117 patients with CTCL who received Targretin ® gel for up to 172 weeks. In the multicenter open label study, 50 patients with CTCL received Targretin ® gel for up to 98 weeks. The mean duration of therapy for these 50 patients was 199 days. The most common adverse events reported with an incidence at the application site of at least 10% in patients with CTCL were rash, pruritus, skin disorder, and pain. Adverse events leading to dose reduction or study drug discontinuation in at least two patients were rash, contact dermatitis, and pruritus. Of the 49 patients (98%) who experienced any adverse event, most experienced events categorized as mild (9 patients, 18%) or moderate (27 patients, 54%). There were 12 patients (24%) who experienced at least one moderately severe adverse event. The most common moderately severe events were rash (7 patients, 14%) and pruritus (3 patients, 6%). Only one patient (2%) experienced a severe adverse event (rash). In the patients with CTCL receiving Targretin ® gel, adverse events reported regardless of relationship to study drug at an incidence of ≥5% are presented in Table 1. A similar safety profile for Targretin ® gel was demonstrated in the Phase I-II program. For the 67 patients enrolled in the Phase I-II program, the mean duration of treatment was 436 days (range 12-1203 days). As in the multicenter study, the most common adverse events regardless of relationship to study drug in the Phase I-II program were rash (78%), pain (40%), and pruritus (40%). Table 1. Incidence of All Adverse Events* and Application Site Adverse Events with Incidence ≥5% for All Application Frequencies of Targretin ® Gel in the Multicenter CTCL Study All Adverse Events Application Site Adverse Events COSTART 5 Body System/Preferred Term N = 50 n (%) N = 50 n (%) * Regardless of association with treatment Includes Investigator terms such as: 1 Contact dermatitis, irritant contact dermatitis, irritant dermatitis 2 Pruritus, itching, itching of lesion 3 Erythema, scaling, irritation, redness, rash, dermatitis 4 Skin inflammation, excoriation, sticky or tacky sensation of skin; NOS = Not Otherwise Specified Skin and Appendages Contact Dermatitis 1 7 (14) 4 (8) Exfoliative Dermatitis 3 (6) 0 Pruritus 2 18 (36) 9 (18) Rash 3 36 (72) 28 (56) Maculopapular Rash 3 (6) 0 Skin Disorder (NOS) 4 13 (26) 9 (18) Sweating 3 (6) 0 Body as a Whole Asthenia 3 (6) 0 Headache 7 (14) 0 Infection 9 (18) 0 Pain 15 (30) 9 (18) Cardiovascular Edema 5 (10) 0 Peripheral Edema 3 (6) 0 Hemic and Lymphatic Leukopenia 3 (6) 0 Lymphadenopathy 3 (6) 0 WBC Abnormal 3 (6) 0 Metabolic and Nutritional Hyperlipemia 5 (10) 0 Nervous Paresthesia 3 (6) 3 (6) Respiratory Cough Increased 3 (6) 0 Pharyngitis 3 (6) 0

adverse reactions table

<table> <caption>Table 1. Incidence of All Adverse Events* and Application Site Adverse Events with Incidence &#x2265;5% for All Application Frequencies of Targretin<sup>&#xAE;</sup> Gel in the Multicenter CTCL Study</caption> <colgroup> <col align="left"/> <col align="center"/> <col align="center"/> </colgroup> <thead> <tr> <th/> <th> <content styleCode="bold">All Adverse Events</content> </th> <th> <content styleCode="bold">Application Site Adverse Events</content> </th> </tr> <tr> <th>COSTART 5 Body System/Preferred Term</th> <th>N = 50 n (%)</th> <th>N = 50 n (%)</th> </tr> </thead> <tfoot> <tr> <td colspan="3"> <paragraph> <caption>*</caption> Regardless of association with treatment</paragraph> <paragraph>Includes Investigator terms such as:</paragraph> <paragraph> <caption> <sup>1</sup> </caption> Contact dermatitis, irritant contact dermatitis, irritant dermatitis</paragraph> <paragraph> <caption> <sup>2</sup> </caption> Pruritus, itching, itching of lesion</paragraph> <paragraph> <caption> <sup>3</sup> </caption> Erythema, scaling, irritation, redness, rash, dermatitis</paragraph> <paragraph> <caption> <sup>4</sup> </caption> Skin inflammation, excoriation, sticky or tacky sensation of skin; NOS = Not Otherwise Specified</paragraph> </td> </tr> </tfoot> <tbody> <tr> <td> <paragraph>Skin and Appendages </paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Contact Dermatitis<sup>1</sup> </paragraph> </td> <td> <paragraph>7 (14)</paragraph> </td> <td> <paragraph>4 (8)</paragraph> </td> </tr> <tr> <td> <paragraph> Exfoliative Dermatitis </paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Pruritus<sup>2</sup> </paragraph> </td> <td> <paragraph>18 (36)</paragraph> </td> <td> <paragraph>9 (18)</paragraph> </td> </tr> <tr> <td> <paragraph> Rash<sup>3</sup> </paragraph> </td> <td> <paragraph>36 (72)</paragraph> </td> <td> <paragraph>28 (56)</paragraph> </td> </tr> <tr> <td> <paragraph> Maculopapular Rash</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Skin Disorder (NOS)<sup>4</sup> </paragraph> </td> <td> <paragraph>13 (26)</paragraph> </td> <td> <paragraph>9 (18)</paragraph> </td> </tr> <tr> <td> <paragraph> Sweating</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph>Body as a Whole</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Asthenia</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Headache</paragraph> </td> <td> <paragraph>7 (14)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Infection</paragraph> </td> <td> <paragraph>9 (18)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Pain</paragraph> </td> <td> <paragraph>15 (30)</paragraph> </td> <td> <paragraph>9 (18)</paragraph> </td> </tr> <tr> <td> <paragraph>Cardiovascular</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Edema</paragraph> </td> <td> <paragraph>5 (10)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Peripheral Edema</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph>Hemic and Lymphatic</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Leukopenia</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Lymphadenopathy</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> WBC Abnormal</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph>Metabolic and Nutritional</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Hyperlipemia</paragraph> </td> <td> <paragraph>5 (10)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph>Nervous</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Paresthesia</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> </tr> <tr> <td> <paragraph>Respiratory</paragraph> </td> <td/> <td/> </tr> <tr> <td> <paragraph> Cough Increased</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> <tr> <td> <paragraph> Pharyngitis</paragraph> </td> <td> <paragraph>3 (6)</paragraph> </td> <td> <paragraph>0</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.